A comprehensive view of hospital/clinical drugs. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Sanofi partners with TrialSpark to pursue acquisition/in-licensing and development of clinical-stage Phase 2, Phase 3 drug candidates in areas of high unmet patient need; firms are jointly targeting six transactions over the next three years
Published: October 04, 2022 by PR Newswire
Novo Nordisk enters license agreement with Ventus Therapeutics to develop, commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors; Ventus receives payment of US$70.0M, with potential for US$633.0M in future payments
Published: September 30, 2022 by Marketline - Deals
FDA approves Regeneron and Sanofi’s injectable Dupixent dupilumab to treat adult patients with prurigo nodularis, making it the first and only medicine specifically indicated to treat the disease; 75,000 adults in the US have prurigo nodularis
Published: September 29, 2022 by PR Newswire
Japan’s Eisai Co. reports its injectable Alzheimer’s drug lecanemab, reduced clinical decline in patients with early-stage Alzheimer’s by 27% in late-stage study; Eisai seeks accelerated approval from FDA, with Eisai and Biogen co-promoting the drug
Published: September 28, 2022 by Associated Press
Johnson & Johnson Details Findings in Drug Development (The Role of Master Protocols In Pediatric Drug Development)
Published: September 28, 2022 by Health & Medicine Business Daily

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count